Aspirin Therapy in Clinical Practice

Secondary Prevention Indications

The European Society of Cardiology recommends aspirin 75-100 mg daily as lifelong therapy for patients with a previous myocardial infarction or revascularization after an initial period of dual antiplatelet therapy (DAPT) 1
Aspirin 75-100 mg daily is recommended for patients with significant obstructive coronary artery disease (CAD) on imaging, according to the European Heart Journal 1
The American Diabetes Association recommends aspirin therapy (75-162 mg/day) as a secondary prevention strategy in patients with diabetes who have a history of atherosclerotic cardiovascular disease 2, 3
Following coronary stenting, aspirin 75-100 mg daily is recommended in combination with clopidogrel for up to 6 months as the default antithrombotic strategy in patients with no indication for oral anticoagulation, as per the European Heart Journal 1

Primary Prevention Indications

The American Diabetes Association suggests that aspirin may be considered as a primary prevention strategy for adults with diabetes and no previous history of vascular disease who are at increased atherosclerotic cardiovascular disease (ASCVD) risk 2, 3
Aspirin (75-162 mg/day) may be reasonable for primary prevention in diabetic patients, both men and women aged ≥50 years with at least one additional major risk factor, who are not at increased risk of bleeding, according to the American Diabetes Association 2, 3
The American Heart Association recommends aspirin (81 mg daily or 100 mg every other day) for prevention of a first stroke among women whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment 4, 5
Aspirin is recommended for primary prevention in persons whose 10-year risk of cardiovascular events is 6-10% when benefits are likely to outweigh risks, as per the American Heart Association 4, 5, 6

Contraindications and Situations Where Aspirin is Not Indicated

Aspirin is not recommended for primary prevention in persons at low risk of cardiovascular events, according to the American Heart Association 4, 5
The American Diabetes Association states that aspirin is not recommended for primary prevention in persons with diabetes or diabetes plus asymptomatic peripheral artery disease in the absence of other established cardiovascular disease 2, 3
Aspirin is not recommended for those at low risk of ASCVD, such as men and women aged <50 years with diabetes with no other major ASCVD risk factors, as the low benefit is likely outweighed by bleeding risks, according to the American Diabetes Association 2, 3
Aspirin use in patients aged <21 years is contraindicated due to the associated risk of Reye syndrome, as recommended by the American Diabetes Association 2, 3

Dosing Considerations

For secondary prevention, aspirin doses of 75-100 mg daily are recommended, according to the European Heart Journal and the American Diabetes Association 1, 2
The most common low-dose tablet in the US is 81 mg, as noted by the American Diabetes Association 2, 3

Special Considerations

In patients with aspirin intolerance, clopidogrel 75 mg daily is recommended as an alternative, according to the European Heart Journal 1
Dual antiplatelet therapy (with low-dose aspirin and a P2Y12 inhibitor) is reasonable for a year after an acute coronary syndrome, as recommended by the American Diabetes Association and other guidelines 2, 7
For patients with unstable angina or non-Q-wave MI, a combination of clopidogrel 75 mg and aspirin 75-100 mg is recommended, according to the Annals of Neurology 8
Patients with uncontrolled hypertension and concomitant use of other nonsteroidal anti-inflammatory agents or anticoagulants have increased risk of serious bleeding, as noted by the American Family Physician and other guidelines 6, 7

Risk-Benefit Assessment

For patients with established cardiovascular disease, the benefits of aspirin therapy far outweigh the bleeding risks, according to the American Diabetes Association 2, 3
In primary prevention, the balance of benefits and risks is most favorable in high-risk persons (five-year risk greater than 3%), as recommended by the American Family Physician 6
For patients over age 70 years without established cardiovascular disease, the balance appears to have greater risk than benefit, according to the American Diabetes Association 2, 3
In adults with risk of ASCVD >1% per year, the number of cardiovascular events prevented will be similar or greater than the number of bleeding events induced, as noted by other guidelines 7

Indications for Low-Dose Aspirin in Patients with Hypertension

Primary Prevention

The American Heart Association recommends low-dose aspirin (75-81 mg daily) for primary prevention in hypertensive patients aged 50 years or older with controlled blood pressure (< 150/90 mmHg) and presence of target organ damage, diabetes, or a 10-year cardiovascular risk > 15% 9, 10
Patients with a 10-year cardiovascular risk ≥ 10% are likely to benefit from low-dose aspirin for primary prevention 11
Hypertensive patients aged 50 years or older with controlled blood pressure (< 150/90 mmHg) and presence of target organ damage are recommended to take low-dose aspirin (75-81 mg daily) for primary prevention 9, 10

Secondary Prevention

Low-dose aspirin (75-81 mg daily) is strongly recommended for secondary prevention in all hypertensive patients with established cardiovascular disease, unless contraindicated 9

Considerations for Aspirin Therapy

The optimal dose of aspirin is 75-81 mg daily, both for primary and secondary prevention, as recommended by the American College of Cardiology 9, 10

Aspirin Use in Patients with Hypertension and Type 2 Diabetes for Primary Prevention

Patient Selection for Aspirin Therapy

The American Diabetes Association recommends aspirin therapy (75-162 mg/day) for primary prevention in diabetic patients aged ≥50 years who have at least one additional major cardiovascular risk factor (family history of premature atherosclerotic cardiovascular disease, hypertension, dyslipidemia, smoking, or albuminuria) 12
Patients with hypertension and diabetes have a two- to fourfold increased risk of dying from cardiovascular disease complications, making them potential candidates for preventive aspirin therapy 12

Evidence Supporting Aspirin Use

The Hypertension Optimal Treatment (HOT) Trial showed that aspirin (75 mg/day) significantly reduced cardiovascular events by 15% and myocardial infarction by 36% in hypertensive patients 12, 13
In the U.S. Physicians' Health Study, diabetic men taking aspirin (325 mg every other day) had a 61% relative risk reduction in myocardial infarction compared to placebo 12
The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that aspirin therapy significantly lowered the relative risk for myocardial infarction to 0.72 (CI 0.55-0.95) 12

Evidence Against Aspirin Use

Recent meta-analyses have found no statistically significant reduction in the risk of major cardiovascular events or all-cause mortality when aspirin was compared with placebo in people with diabetes and no pre-existing cardiovascular disease 14, 15

Bleeding Risk Considerations

Aspirin increases the relative risk of major gastrointestinal bleeding (relative risk 1.6), even with relatively low doses 13
Estimated rates of major gastrointestinal bleeding are approximately 2-4 per 1,000 middle-aged persons (4-12 per 1,000 for older persons) given aspirin for 5 years 16, 17
Aspirin may increase rates of hemorrhagic strokes by 0-2 per 1,000 persons over 5 years 16, 18
Contraindications to aspirin therapy include allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding, and clinically active hepatic disease 13

Special Considerations

Aspirin therapy should be avoided in patients with uncontrolled hypertension due to increased bleeding risk 19
Aspirin does not appear to increase risk for retinal or vitreous hemorrhage in diabetic patients with retinopathy 13

Antiplatelet Therapy in Patients with Hypertension and Diabetes

Introduction to Aspirin Therapy

The American College of Physicians recommends aspirin therapy (75-162 mg/day) for primary prevention in patients with both hypertension and diabetes, aged ≥50 years, with at least one additional major cardiovascular risk factor, and controlled blood pressure, though the evidence remains controversial and bleeding risks must be carefully weighed 20

Evidence for Primary Prevention

The European Society of Cardiology notes that the HOT trial demonstrated that 75 mg aspirin daily reduced major cardiovascular events by 15% and myocardial infarction by 36% in well-controlled hypertensive patients with diabetes, though non-fatal major bleeds were twice as common 21
The American Heart Association acknowledges that aspirin provided additional cardiovascular risk reduction beyond blood pressure control alone in the HOT study subgroup with diabetes 21
Recent meta-analyses found no statistically significant reduction in major cardiovascular events or all-cause mortality when aspirin was compared with placebo in people with diabetes and no pre-existing cardiovascular disease, as reported by the European Heart Journal 22
Aspirin significantly reduced myocardial infarction in men but not in women in primary prevention trials, according to the American College of Cardiology 20

Bleeding Risk Considerations

The American College of Cardiology states that non-fatal major bleeds occur approximately twice as frequently with aspirin therapy 21

Clinical Decision Algorithm

The American Heart Association recommends that aspirin 75-162 mg daily is strongly recommended for patients with established atherosclerotic cardiovascular disease, regardless of diabetes or hypertension status 20
Age ≥50 years with diabetes AND hypertension qualifies as intermediate-to-high risk, as noted by the American College of Physicians 20
Patients with ≥1 additional risk factor beyond diabetes and hypertension are candidates for aspirin, according to the American College of Cardiology 20

Dosing Recommendations

The American College of Cardiology recommends the optimal aspirin dose for both primary and secondary prevention is 75-162 mg daily 20
Using the lowest effective dose (75-81 mg) may help reduce adverse effects while maintaining efficacy, as reported by the American Heart Association 20

Alternative Antiplatelet Therapy

The American College of Cardiology recommends clopidogrel 75 mg daily as an alternative for patients with documented aspirin allergy 20

Common Pitfalls to Avoid

The American Heart Association advises against initiating aspirin in low-risk patients (age <50 years with diabetes and no other major risk factors) - bleeding risks outweigh minimal benefits 20
The American College of Cardiology notes that aspirin reduces MI in men but not women, while reducing stroke in women but not men, in primary prevention data 20

Shared Decision-Making

The American Heart Association recommends engaging in shared decision-making that weighs the patient's 10-year cardiovascular risk, individual bleeding risk factors, patient preferences, and the understanding that benefits are most clearly established for secondary prevention 20
The American College of Cardiology suggests using risk calculators to assess the patient's 10-year cardiovascular risk, as noted in the journal Circulation 23

Timing of Low-Dose Aspirin Administration for Cardiovascular Event Prevention

Guideline Recommendations on Aspirin Administration

The American Diabetes Association recommends a daily dose of 75-162 mg aspirin for cardiovascular event prevention, with 81 mg being the most common formulation in the U.S., and emphasizes that the dose is more important than the timing of administration 24, 25
The American Diabetes Association and the U.S. Preventive Services Task Force do not specify a preferred time of day for aspirin administration, focusing instead on dose, frequency, and patient selection criteria 24, 26, 27
The optimal frequency of aspirin administration is once daily, according to the American Diabetes Association 24, 26

Dosing Considerations

The American Diabetes Association emphasizes that using the lowest effective dose of 75-81 mg aspirin daily reduces bleeding risk while maintaining efficacy 24, 25
The ADAPTABLE trial showed no difference in cardiovascular events or bleeding between 81 mg and 325 mg daily aspirin doses, supporting the use of the lower dose 24, 25

Safe Daily Aspirin Dosage for Cardiovascular Prophylaxis in Elderly Women

Dosing Recommendations

For elderly women with established cardiovascular disease, aspirin 75-162 mg daily is strongly recommended, with 75-81 mg being the preferred dose, as recommended by the American College of Cardiology 28
Women ≥65 years with controlled blood pressure may be considered for aspirin 81 mg daily or 100 mg every other day when cardiovascular risk is sufficiently high (>6-10% 10-year risk) 29

Special Considerations

Elderly women face substantially higher bleeding risk with aspirin, which must be carefully weighed against cardiovascular benefits, with major bleeding events occurring at approximately 5 per 1,000 per year in real-world settings 30
For diabetic women with established cardiovascular disease, aspirin 75-162 mg daily is strongly recommended 30, 28
The American College of Cardiology recommends that lower doses (75-81 mg) provide equivalent cardiovascular protection to higher doses while significantly reducing bleeding complications 28

Alternative Therapies

For elderly women with documented aspirin allergy requiring antiplatelet therapy, clopidogrel 75 mg daily should be substituted, as recommended by the American College of Cardiology 30